Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Evotec AG ( (EVO) ) is now available.
Evotec SE reported that its fourth-quarter and full-year 2025 revenues reached €253.3 million and €788.4 million, respectively, with adjusted EBITDA of €58.0 million and €41.1 million, landing at the high end of guidance and supported by milestone payments from Bristol Myers Squibb and Bayer collaborations. The year also saw the December 2025 sale of its Toulouse biologics site to Sandoz for more than $650 million plus biosimilar-linked milestones and royalties, strengthening a capital-light model and underscoring Evotec’s positioning in biologics and biosimilars.
Operationally, Evotec advanced key clinical assets, including Bristol Myers Squibb’s molecular glue BMS-986506 moving into Phase 1 in March 2026 and Bayer’s Alport syndrome program entering Phase 2 in December 2025, while expanding Just – Evotec Biologics through a BARDA antibody manufacturing award and a January 2026 Gates Foundation grant for AI-driven antibody developability. The company also began implementing its “Horizon” operating model in March 2026, cutting its footprint to 10 sites, building Centers of Excellence, targeting about €75 million in run-rate savings by end-2027, and signaling 2026 as a transition year with expected revenues of €700–780 million and modest EBITDA as it moves toward a more profitable, growth-focused profile.
Governance and leadership changes complemented the strategic shift, with the April 2025 appointment of Dr. Ashiq H. Khan as Chief Commercial Officer to reinforce commercial execution and an April 2026 nomination of industry veteran Dieter Weinand as prospective Chairman of the Supervisory Board. Evotec further highlighted portfolio monetization with an expected upfront payment of about $100 million, plus potential milestones, from Gilead’s planned acquisition of its portfolio company Tubulis announced in April 2026, marking the fourth realization from its EVOequity investments and adding financial flexibility for its ongoing transformation.
The most recent analyst rating on (EVO) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.
Spark’s Take on EVO Stock
According to Spark, TipRanks’ AI Analyst, EVO is a Neutral.
Evotec AG’s overall stock score is primarily impacted by its weak financial performance and concerning valuation metrics. The company is struggling with profitability and cash flow issues, reflected in a negative P/E ratio and lack of dividend yield. Technical analysis shows a bearish trend, further weighing on the score. Despite some positive developments from the earnings call, such as growth in the Biologics segment and strategic partnerships, these are not enough to offset the significant financial challenges.
To see Spark’s full report on EVO stock, click here.
More about Evotec AG
Evotec SE is a Germany-based drug discovery and development company that partners with pharmaceutical and biotech firms to advance small-molecule and biologics programs. Through its Drug Discovery and Preclinical Development division and Just – Evotec Biologics platform, the group focuses on high-value services, AI-enabled R&D and technology-centered biologics manufacturing, including participation in fast-growing biosimilar and global health markets.
Average Trading Volume: 142,143
Technical Sentiment Signal: Sell
Current Market Cap: $927.7M
Find detailed analytics on EVO stock on TipRanks’ Stock Analysis page.